NDA 208341 · Gilead Sciences INC
Epclusa
Sofosbuvir, Velpatasvir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Dec 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jun 28, 2016
Approved uses
7
Original approval plus efficacy supplements
Registered trials
343
110 Phase 3, 6 recruiting
FAERS reports
12,830
3,897 serious, 592 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with sofosbuvir and velpatasvir. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed...
What it is approved for
From the label in effect Mar 6, 2025.
Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4 ) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. Sofosbuvir and velpatasvir is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection ( 1 ): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin.
Mechanism: Sofosbuvir and velpatasvir tablets (400 mg/100 mg) are a fixed-dose combination of sofosbuvir and velpatasvir, which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 27, 2022 Supplement 19 · Efficacy LabelLetter
- Jun 10, 2021 Supplement 17 · Efficacy · priority review OrphanLabelLetter
- Jul 14, 2020 Supplement 15 · Efficacy LabelLetter
- Mar 19, 2020 Supplement 14 · Efficacy · priority review OrphanLabelLetter
- Nov 15, 2019 Supplement 12 · Efficacy LetterLabel
- Aug 1, 2017 Supplement 1 · Efficacy LetterLabel
- Jun 28, 2016 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyOrphanLabelReviewLetter
2 products under this application
- EPCLUSA · SOFOSBUVIR 400MG; VELPATASVIR 100MG · TABLET, ORAL · Prescription
- EPCLUSA · SOFOSBUVIR 200MG; VELPATASVIR 50MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sofosbuvir" as an intervention, any sponsor and status, largest first.
- Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab ModelStatus unknown
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT03488485 · 50,000 participants (planned) · Start Jun 18, 2016 · Primary completion Dec 2020
Drug: Direct Acting Antivirals · For: Chronic Hepatitis c
Sites: Chandigarh, India
- Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)Pivotal-lookingRecruiting
Oswaldo Cruz FoundationAcademic, hospital or other
NCT06306300 · 30,000 participants (planned) · Start Jul 4, 2022 · Primary completion Dec 31, 2026
Drug: Specialist - Epclusa 400Mg-100Mg Tablet; Non- specialist - Epclusa 400Mg-100Mg Tablet · For: Hepatitis C
Sites: Rio de Janeiro, Brazil · 2 sites in all
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaActive, not recruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT05992077 · 21,000 participants (planned) · Start Aug 7, 2023 · Primary completion Jan 31, 2026
Drug: Sofosbuvir/Daclatasvir · For: HCV Infection
Sites: Battambang, Cambodia; Phnom Penh, Cambodia; Siem Reap, Cambodia · 4 sites in all
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionPivotal-lookingCompleted
Tanta UniversityAcademic, hospital or other
NCT02992457 · 10,000 participants · Start Jan 2015 · Primary completion Dec 2018
Drug: Sofosbuvir; Ribavirin and 6 more · For: Hepatitis C
Sites: Tanta, Egypt · 2 sites in all
Kirby InstituteGovernment (non-federal)
NCT02064049 · 3,692 participants · Start Oct 2014 · Primary completion Nov 2019
Drug: Sofosbuvir/velpatasvir · For: Hepatitis C
Sites: Goulburn, Australia; Lithgow, Australia; Windsor, Australia · 4 sites in all
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and TanzaniaRecruiting
Médecins du MondeAcademic, hospital or other
NCT06159504 · 3,040 participants (planned) · Start Oct 3, 2024 · Primary completion Dec 2026
Drug: sofosbuvir/velpatasvir (SOF/VEL) · For: Hepatitis C; RDT
Sites: Yerevan, Armenia
- COVID-19 Prophylaxis South Africa (COVER HCW)Pivotal-lookingCompleted
University of Witwatersrand, South AfricaAcademic, hospital or other
NCT04561063 · 1,950 participants · Start Dec 8, 2020 · Primary completion Feb 28, 2022
Drug: Nitazoxanide; Sofosbuvir/Daclatasvir · For: Covid19; SARS-CoV Infection
Sites: Johannesburg, South Africa · 2 sites in all
- Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)Pivotal-lookingStatus unknown
Macfarlane Burnet Institute for Medical Research and Public Health LtdAcademic, hospital or other
NCT05016609 · 1,800 participants (planned) · Start Mar 9, 2022 · Primary completion Apr 2024
Drug: Sofosbuvir/Velpatasvir (Gilead) · For: Hepatitis C
Sites: Clayton South, Australia; Collingwood, Australia; Corio, Australia · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,628
- headache2,218
- nausea1,178
- diarrhoea664
- drug ineffective558
- insomnia514
- hepatitis c413
- treatment failure337
- vomiting330
- death312
- dizziness287
- rash259
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 400 |
| 2017 | 2,137 |
| 2018 | 2,222 |
| 2019 | 2,663 |
| 2020 | 1,724 |
| 2021 | 1,071 |
| 2022 | 990 |
| 2023 | 570 |
| 2024 | 449 |
| 2025 | 373 |
| 2026 | 231 |
Recalls
1 FDA enforcement reports for this application.
Mar 7, 2025 · Class II · Terminated
Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Epclusa (Sofosbuvir/Velpatasvir)
2024 spending
$758M
Beneficiaries
12,242
31,431 claims
Per beneficiary
$61,921
$848.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $867,053,907 |
| 2021 | $938,659,922 |
| 2022 | $899,944,724 |
| 2023 | $877,398,115 |
| 2024 | $758,041,570 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drug-associated pulmonary arterial hypertension.
McGee M, Whitehead N, Martin J, et al. · Clin Toxicol (Phila) 2018 · Systematic Review
- Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Sokhela S, Bosch B, Hill A, et al. · J Antimicrob Chemother 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions.
Noskov S, Arefeva A, Radaeva K, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Comparative Study
- Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.
Jonas MM, Romero R, Rosenthal P, et al. · J Pediatr Gastroenterol Nutr 2024 · Multicenter Study, Clinical Trial, Phase II
- Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.
Caldeira D, Rodrigues FB, Duarte MM, et al. · Drug Saf 2018 · Meta-Analysis, Systematic Review
- Cost-effectiveness of treating hepatitis C in Seychelles.
Adeline NJF, Geue C, Hermami MR · Pan Afr Med J 2019 · Systematic Review
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.